Cordlife (SGX:P8A) received a letter from Singapore's Ministry of Health, directing it to cease collection, testing, processing and storage of CBUs from infant donors from Nov. 26, according to a Monday filing with the Singapore Exchange.

Shares of the cord blood collection company were down nearly 7% in Tuesday trade.

The company has been allowed to store existing CBUs, but it must ensure that storage conditions of all existing CBUs are appropriate and regularly monitored. It is also permitted to facilitate the transfer of existing CBUs to another local or accredited overseas provider, facilitate retrieval of existing units for clinical purposes and dispose of existing units if it has been instructed or authorized by a client, subject to certain conditions.

Cordlife has also been ordered to remove its current clinical governance officer and find a suitable, qualified replacement.

The conditions will remain in force even if the company is granted a renewed CBBS license for one year in January 2026 and until it demonstrates its ability to meet regulatory requirements.

As of now, the company is not allowed to carry out any type of cord blood banking services except for maintaining the safety and quality of existing ones.